Germany's Merck KGaA has announced plans to buy AZ Electronic Materials, which supplies high-tech materials for the electronics industry, for about 1.6 billion pounds ($2.6 billion). Pharmaceutical and high-tech materials company Merck said Thursday that it will offer 403.5 pence ($6.61) in cash.
Forest Laboratories says it plans to cut about 500 jobs as part of a plan to trim $500 million...
Under the terms of the agreement, Forest will make an upfront payment of $240 million and...
Biopharm GmbH, Heidelberg, announced today that they have signed an agreement with Merck to...
Merck said Monday that U.S. regulators will make a faster decision on an IV formulation of its antifungal drug Noxafil. Merck said the IV version of the drug will get a priority review. That means the Food and Drug Administration will make a decision in six months instead of the usual 10 months.
Merck KGaA, Darmstadt, Germany, has announced an € 80 million investment in a new pharmaceutical manufacturing facility, to be located in the Nantong Economical Technological Development Area (NETDA), in the Greater Shanghai region (Yangtze River Delta area).
Merck announced Friday that it would cease active ingredient production at one of its plants in Puerto Rico in a blow to a city once considered a pharmaceutical hub. The company said production at a plant in the north coastal city of Barceloneta will end by late 2014 as part of a global restructuring.
Merck said that its new human papillomavirus vaccine was about 97 percent effective in blocking precancerous lesions caused by strains of the virus that are not stopped by Merck's vaccine Gardasil. Merck & Co. said it expects to file for marketing approval of the new vaccine, which is designated V503, before the end of 2013.
Merck & Co. will put a positive spin on its Oct. 1 announcement of major job cuts and yet another restructuring, and discuss progress on its experimental drugs, when it reports third-quarter results before the market opens Monday.
Merck announced today that ZOSTAVAX® (Zoster Vaccine Live), the company's vaccine to help prevent shingles, received the Prix Galien USA 2013 Award for Best Biotechnology Product.
Shares of Merck slipped Monday before markets opened and after another analyst lowered his rating on the drug developer, which recently announced job cuts and is dealing with the expiration of patents protecting key products. Bernstein analyst Dr. Tim Anderson said in a Monday research note that Merck appears to have only average prospects for long-term revenue and earnings per share growth.
Merck said Tuesday that it plans to cut another 8,500 jobs as part of a plan to reduce its annual costs by about $2.5 billion by the end of 2015. In addition, Merck will move its headquarters from Whitehouse Station, N.J., to existing facilities in Kenilworth, N.J.
Merck has announced a global initiative to sharpen its commercial and research and development (R&D) focus. The multi-year initiative will enable Merck to better target its resources behind those opportunities that have the potential to deliver the greatest return on investment, including bolstering its pipeline and implementing a more agile operating model, with a significantly reduced, more flexible cost structure.
The FDA’s letter raised concerns about operational aspects of a hypersensitivity study that the agency had requested in 2008. Merck is evaluating the Complete Response Letter and expects to be able to determine a path forward in the very near future.
AstraZeneca PLC will take over clinical development of a potential ovarian cancer treatment from Merck & Co. under a new licensing deal the drugmakers announced today. As part of the deal, London-based AstraZeneca will pay Merck $50 million upfront and possible future payments tied to development and regulatory milestones as well as sales.
Idaho's lawsuit against several major pharmaceutical companies over allegations of inflated drug prices has come to an end with the state recovering more than $28 million in damages. Attorney General Lawrence Wasden announced that his office has completed six years of litigation against Watson Pharmaceuticals, Johnson & Johnson, Merck and 30 other pharmaceutical companies.
Merck announced today that James Stewart (52) will become Chief Information Officer (CIO) of the Merck Group as of October 1, 2013. In his new position, Stewart will report to Kai Beckmann, member of the Merck Executive Board. Stewart succeeds Frédéric Wohlwend, who has decided to pursue new opportunities outside Merck.
Long-term results from a major federal study ease worries about the safety of a hormone-blocking drug that can lower a man's chances of developing prostate cancer. The drug cut prostate cancer risk by 30 percent without raising the risk of dying of an aggressive form of the disease as earlier...
The FDA has approved Tivicay (dolutegravir), a new drug to treat HIV-1 infection. Tivicay is an integrase strand transfer inhibitor that interferes with one of the enzymes necessary for HIV to multiply. It is a pill taken daily in combination with other antiretroviral drugs.
Merck KGaA bounced back from losses this time last year to record a net profit of 316 million euros ($420 million) in the second quarter. The Darmstadt-based company, which produces the liquid crystal used in TV screens and life sciences laboratory...
Merck & Co. says its second-quarter profit fell by half because of generic competition cutting into sales and acquisition and other charges. The maker of blockbuster diabetes pill Januvia and Gardasil, a vaccine against sexually transmitted cancers, says second-quarter net income was $906 million, or 30 cents per share, down from $1.79 billion, or 58 cents per share, a year earlier.
Merck & Co. will emphasize its progress in developing a new crop of prescription drugs to offset revenue losses from generic competition to older ones, particularly Singulair, when it reports second-quarter results before the stock market opens Tuesday. CEO Kenneth Frazier will likely note that Merck, the world's third-biggest drugmaker by revenue, now has a half-dozen experimental drugs under review.
The European Medicines Agency said Friday it uncovered no new evidence of pancreas-related safety issues after reviewing a group of recently approved diabetes drugs. The agency's Committee for Medicinal Products for Human Use reviewed the safety of so-called GLP-1 diabetes therapies after a study...
Merck announced that the New Drug Application for its investigational anti-thrombotic medicine, vorapaxar, has been accepted for standard review by the U.S. Food and Drug Administration (FDA).
Merck & Co. Inc. said that the Food and Drug Administration has cancelled a Thursday meeting to review its drug designed to help patients "wake up" after surgery with anesthesia. The company said in a statement that the FDA wants more time to...
Merck has announced today that the FDA has approved new labeling for ISENTRESS® (raltegravir) Film-coated Tablets, Merck’s integrase inhibitor for the treatment of HIV-1 infection in adult patients as part of combination HIV therapy.
Merck says federal regulators have ruled that they won't approve high doses of its experimental insomnia medication because of concerns about their safety. But Merck says the Food and Drug Administration has indicated it would approve lower...
A vaccine against a cervical cancer virus cut infections in teen girls by half in the first study to measure the shot's impact since it came on the market. The results impressed health experts and a top government top health official called them striking.
Shares of Bristol-Myers Squibb Inc. and Merck & Co. are up about 5 percent each after the drugmakers announced encouraging results on experimental cancer medicines over the weekend. Both companies' drugs for advanced cases of melanoma are in a new class that helps the patient's immune system...
- Page 1